

# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Amphetamine salt combo (Mydayis)

### Notes:

- ^ Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.
- \*\*Adequate trial of a short acting agent is further defined as wearing off that is not resolved by increasing the dose and the frequency to a minimum of twice daily OR clinically significant side effects related to the short-acting dosage form that cannot be resolved by adjusting the dose or timing.
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria:** Non-formulary **amphetamine salt combo (Mydayis)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) or dexmethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary **amphetamine salt combo (Mydayis)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) or dexmethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Amphetamine salt combo (Mydayis)

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **amphetamine salt combo (Mydayis)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient is over 21 year of age
  - Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
  - Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
  - Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- OR -**
- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and patient is age 6 to 20 years old and stable on medication